Seeking Alpha

Amgen (AMGN -1.2%) continues its slide on the back of the FDA's rejection of Xgeva yesterday,...

Amgen (AMGN -1.2%) continues its slide on the back of the FDA's rejection of Xgeva yesterday, spurred on today by a downgrade to Perform at Oppenheimer, citing a lack of near-term catalysts for the drug maker over the near term.
Comments (1)
  • cholee65
    , contributor
    Comments (38) | Send Message
     
    Amgen has to be looking to beef up their pipeline now, they should look at ASTX. Here's a decent company that CEO's last company Genzyme bought for a billion: http://bit.ly/xrPxih
    23 Feb 2012, 01:51 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs